Helicobacter Pylori
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 14, 2005; 11(18): 2726-2732
Published online May 14, 2005. doi: 10.3748/wjg.v11.i18.2726
Table 2 Characteristics of bismuth- or PPI-based quadruple therapies.
RefsCombination regimensDoseTreatment durationEradication rate (ITT)
P
PUD
NUD
N/T.N (%)N/T.N (%)
17CBS/Met/Tet/Lan120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.1d22/33 (66.7)5/13 (38.5)0.16
17CBS/Met/Tet/Lan120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.2 d26/35 (74.3)20/40 (50)0.06
13Amo/Cla/Tin/Ome1 g b.i.d./500 mg b.i.d./500 mg b.i.d./20 mg b.i.d.5 d1230/31 (96.8)31/34 (91.2)0.68
18Bis/Met/Tet/Lan120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.7 d91/101 (90.1)107/118 (90.7)0.93
19Bis/Met/Tet/Ome120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.10 d53/57 (93)46/49 (93.9)0.84
8Bis/Met/Tet/Ome120 mg q.i.d./500 mg t.i.d./500 mg q.i.d./20 mg b.i.d.14 d9/11 (81.8)8/13 (61.5)0.53